Kinesins and Cancer, Softcover reprint of the original 1st ed. 2015

This interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development.

Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future.

The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail.

Preface     
                                                                                                             1 The kinesin superfamily
Kristen J. Verhey, Jared C. Cochran and Claire E. Walczak                        
 
2 The discovery and development of Eg5 inhibitors for the clinic
James A.D. Good, G. Berretta, Nahoum G. Anthony and Simon P.Mackay                                                                                                    

3 Mechanism of action of Eg5 inhibitors
Robert A.Cross                                                                                                       

4 Clinical trials of mitotic kinesin inhibitors
Steven S.Rosenfeld                                                                                                 

5 Kif15; a useful target for anti-cancer therapy?
Roy G.H.P. van Heesbeen and Rene H.Medema 

 6 Down-regulating CENP-E activity: for better or for worse
Julien Espeut and ArianeAbrieu

7  The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug target
Vaishali Pannu, Padmashree C.G. Rida and Ritu Aneja                                       

8  Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapy
Anutosh Ganguly and Fernando  Cabral                                                                   

9 Chromokinesins in genome maintenance and cancer
Manjari Mazumdar and Tom Misteli                                                                       

10 Kif14: a clinically relevent kineisn and potential target for cancer therapy
Brigitte L. Theriault and Timothy W. Corson                                                          

11 Kinesin-8 members and their potnetial as biomarker or therapeutic target
Thomas U. Mayer and Silke Hauf                                                                           

12 The kinesin-6 members MKLP1, MKLP2 and MPP1
Ryan D. Baron and Francis Barr                                                                            

13  Non-motor spindle proteins as cancer chemotherapy targets
Bob Margolis and Mythili Yenjerla                                                                          

14  Inhibitors of mitotic kinesins for cancer treatment: consequences for neurons
Olga I. Kahn and Peter Baas                                                                                                Index                                                                                                                          

Covers the entire, interdisciplinary field of kinesins and cancer through expert contributions

Offers a timely reference standard on the relevance of kinesins to cancer treatment

Contributes to potential initial validation of mitotic kinesins as targets for drug development in cancer chemotherapy